I don't know if we are going to grab a quick $10-$15 on TEAM and sell at $220 or really commit. Extremely abbreviated morning as i pack up and head back to Ct! I am crazy in the head now with the sudden realization my summer ends Fri.- Gots to get a few more swims in. Got to get the boiler going it was 48 this morning//
BUY IDEA #1--> PINTRUST WE TALKED ABOUT PINS LAST NIGHT. I DON'T THINK WE'LL GET MUCH MORE THAN $3 OR $4 UPSIDE BUT WHY NOT? BUY IDEA #2--> Tidewater This is the most powerful oil name. -Tidewater price target raised to $91 from $75 at BTIG » 07:15 TDW
BUY IDEA #3--> ADD TO HELIX WE ALREADY OWN THIS GREAT NAME FROM RADIO GUMMY OUR LAST SUPERSTAR STOCK PICKING THREAD.. $7-----$10 BUT I THINK WE CAN GET MORE. A LOT MORE. #12->Helix Energy Solutions Group, Inc. (HLX) NYSE - NYSE Delayed Price. 6.84+0.09 (+1.33%) Helix Energy price target raised to $17 from $14 at BTIG » 07:15 HLX
--ClearSign receives new funding for its Hydrogen Ultra Low NOx burner project » 07:13 CLIR --Pinterest price target raised to $38 from $35 at Rosenblatt » 07:07 PINS --Amazon seasonal hiring plans 'a bullish leading indicator,' says Morgan Stanley » 06:54 AMZN --Wingstop upgraded to Outperform from Neutral at Wedbush » 06:39 WING --Red Cat subsidiary signs $1.8M contract with U.S. CBP » 06:28 RCAT
TODAYS GUMMY- RVNC- $13.50 --Revance selloff brings 'compelling' risk/reward, says Barclays » 06:14 RVNC
--On Holding initiated with a Buy at Needham » 05:54 ONON Needham --Planet Labs CEO buys $269.8K in common stock » 18:16 PL
TODAY'S 2ND GUMMY- PL Planet Labs PBC (PL) NYSE - NYSE Delayed Price. 2.7000+0.0100 (+0.37%) At close: September 19 04:00PM EDT 2.8400 +0.14 (+5.19%)<------------------- Pre-Market: 07:22AM EDT Insider Buying: Co-Founder and CEO William Marshall Acquires 100,000 Shares of Planet Labs PBC (PL)
WHAT HAPPENED: Technology Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke Licensing 04:18 PM ET 09/19/2023 Revance Therapeutics (RVNC) is reversing course to stay competitive with AbbVie's (ABBV) market-leading aesthetics drug, Botox — and RVNC stock crashed Tuesday in response. The company said earlier this year it was going after "prestige" accounts with its Daxxify, the newest in a class of botulinum toxins that smooth frown lines. But, during an investor day update, Revance said it's cutting Daxxify prices "to be priced competitively with Botox" and "accelerate market share expansion." The news is likely to put a damper on analysts' expectation for $247.4 million in sales this year. On today's stock market, RVNC stock crashed 17.3% to 13.81. Earlier, shares fell as much as 33.5%. Revance stock was among the worst-performing biotech stocks on Tuesday. RVNC Stock: Competing With AbbVie AbbVie is easily the market leader for botulinum toxin injections. It first gained approval in 2002. Now, Botox Cosmetic is a $2 billion-plus annual product. Sales are expected to top $3 billion in 2025 and $4 billion just three years later, according to FactSet.
Revance removed 'last roadblock' for Daxxify, says William Blair » 07:03 RVNC, ABBV Revance price target lowered to $44 from $50 at Piper Sandler » 06:50 RVNC
PT $44 // PARTIALLY DE RISKED STK $13.50 Revance Therapeutics, Inc. (RVNC) NasdaqGM - NasdaqGM Real Time Price. 13.81-2.89 (-17.31%) At close: September 19 04:00PM EDT 13.48 -0.33 (-2.39%)<-------------------- Pre-Market: 07:07AM EDT